Detalhe da pesquisa
1.
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.
Cell
; 164(3): 433-46, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26824656
2.
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Clin Immunol
; 218: 108517, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585295
3.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Proc Natl Acad Sci U S A
; 113(30): E4338-47, 2016 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402769
4.
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Breast Cancer Res
; 15(2): 308, 2013 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23566381
5.
Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα.
J Immunol
; 185(6): 3685-93, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20696864
6.
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Breast Cancer Res
; 13(2): R30, 2011 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21396117
7.
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Immunotherapy
; 13(12): 977-987, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34184542
8.
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Clin Cancer Res
; 26(23): 6299-6309, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998963
9.
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Eur J Pharmacol
; 885: 173505, 2020 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861662
10.
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Arch Biochem Biophys
; 475(2): 156-63, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18468507
11.
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.
Nat Cell Biol
; 18(5): 572-8, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27088857
12.
Electrophoretic mobility shift assay analysis of NFκB transcriptional regulation by nuclear IκBα.
Methods Mol Biol
; 809: 49-62, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113267
13.
Chromatin immunoprecipitation analysis of NFκB transcriptional regulation by nuclear IκBα in human macrophages.
Methods Mol Biol
; 809: 121-34, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113272
14.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Cancer Discov
; 2(11): 1048-63, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915751
15.
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Mol Cancer Res
; 9(2): 183-94, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21224428